“We will update our rating and PT later. We summarize 3Q:17 performance in Exhibit 1.”,” Mizuho’s analyst wrote.
Other analysts have also recently issued reports about the stock. Deutsche Bank AG set a $13.00 target price on shares of Endo International PLC and gave the company a buy rating in a research report on Wednesday, August 9th. ValuEngine upgraded shares of Endo International PLC from a hold rating to a buy rating in a research report on Monday, October 2nd. Zacks Investment Research upgraded shares of Endo International PLC from a hold rating to a buy rating and set a $9.75 target price on the stock in a research report on Wednesday, October 11th. Morgan Stanley decreased their target price on shares of Endo International PLC from $12.00 to $8.00 and set an equal weight rating on the stock in a research report on Thursday, August 10th. Finally, Oppenheimer Holdings, Inc. restated a hold rating on shares of Endo International PLC in a research report on Sunday, July 23rd. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $11.67.
Shares of Endo International PLC (NASDAQ ENDP) opened at $6.69 on Friday. The company has a current ratio of 1.08, a quick ratio of 0.86 and a debt-to-equity ratio of 10.78. The stock has a market cap of $1,547.56, a PE ratio of 1.43 and a beta of 0.53. Endo International PLC has a 1 year low of $5.77 and a 1 year high of $18.63.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Thursday, November 9th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.06. The firm had revenue of $786.90 million for the quarter, compared to analysts’ expectations of $794.93 million. Endo International PLC had a negative net margin of 126.97% and a positive return on equity of 66.98%. The business’s revenue was down 11.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.01 EPS. sell-side analysts anticipate that Endo International PLC will post 3.54 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in the company. HL Financial Services LLC lifted its position in shares of Endo International PLC by 1.0% in the 2nd quarter. HL Financial Services LLC now owns 52,800 shares of the company’s stock worth $590,000 after purchasing an additional 500 shares during the period. Amalgamated Bank lifted its position in shares of Endo International PLC by 2.0% in the 1st quarter. Amalgamated Bank now owns 32,357 shares of the company’s stock worth $361,000 after purchasing an additional 619 shares during the period. Meeder Asset Management Inc. lifted its position in shares of Endo International PLC by 1.4% in the 2nd quarter. Meeder Asset Management Inc. now owns 48,699 shares of the company’s stock worth $544,000 after purchasing an additional 677 shares during the period. Capstone Asset Management Co. lifted its position in shares of Endo International PLC by 3.1% in the 2nd quarter. Capstone Asset Management Co. now owns 32,035 shares of the company’s stock worth $358,000 after purchasing an additional 960 shares during the period. Finally, Arizona State Retirement System lifted its position in shares of Endo International PLC by 1.5% in the 2nd quarter. Arizona State Retirement System now owns 83,700 shares of the company’s stock worth $935,000 after purchasing an additional 1,200 shares during the period. 90.50% of the stock is owned by hedge funds and other institutional investors.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.